Binnopharm Group takes Favipiravir to Russian market

Binnopharm Group, a pharmaceutical company forming part of Sistema Group, has marketed the first batch of Favipiravir for Russian consumers. The medicine has been recommended by the Ministry of Health for COVID-19 treatment. The Group received marketing authorisation for the drug in September 2021.

“COVID-19 cases are at a high-water mark. To help fight the pandemic, we did our best to make the medicine available for patients in the shortest possible time. Currently, it is manufactured in India under a contract, but we are working on localising production at a plant in Obolensk, Moscow Region,” says Rustem Muratov, CEO of Binnopharm Group.
According to Alpharm, in the second half of 2021 Favipiravir sales in volume terms increased fivefold compared to the previous six months, exceeding eight million units for the year.

The Russian Health Ministry has included favipiravir in the COVID-19 treatment protocol as part of its Prevention, Diagnosis, and Treatment of New Coronavirus Infection (COVID-19) interim guidelines, version 14 dated 28 December 2021.